Drugs / pINGmuTyr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00471133 | Apr 2007 → May 2010 | cutaneous melanoma, uveal melanoma | Ichor Medical Systems Incorporated | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pINGmuTyr | “To further define the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA vaccine (pINGmuTyr) in malignant melanoma patients.” PMID 24829756 ↗ Nov 2013 |
| Modality | Vaccine | “a murine Tyr DNA vaccine (pINGmuTyr)” PMID 24829756 ↗ Nov 2013 |
| Route | Intramuscular | “the vaccine will be administered intramuscularly” NCT00471133 ↗ |